
April 16 (Reuters) - British medical device maker Belluscura BELLB.L said on Wednesday that its products sold in the United States would face tariff of up to 20% and that the company was evaluating how it could cut down tariff and production costs in the long term.
The company, which focuses on developing portable oxygen technology, also announced that its finance chief, Simon Neicheril, had stepped down.